Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer
about
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell linesLoss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubismThe SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motilityThe role of Src in solid tumorsThe molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targetsThe molecular rationale of Src inhibition in colorectal carcinomasα-Actinin-4 enhances colorectal cancer cell invasion by suppressing focal adhesion maturationDasatinib sensitizes KRAS mutant colorectal tumors to cetuximabSpatiotemporal regulation of Src and its substrates at invadosomesGlobal phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancerTransforming growth factor-alpha prevents detachment-induced inhibition of c-Src kinase activity, Bcl-XL down-regulation, and apoptosis of intestinal epithelial cellsSrc tyrosine kinase phosphorylation of nuclear receptor HNF4α correlates with isoform-specific loss of HNF4α in human colon cancer.Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypesC-terminal Src kinase controls development and maintenance of mouse squamous epithelia.Actin stress fiber organization promotes cell stiffening and proliferation of pre-invasive breast cancer cells.Identification of the SRC pyrimidine-binding protein (SPy) as hnRNP K: implications in the regulation of SRC1A transcriptionFibroblast growth factor 2 causes G2/M cell cycle arrest in ras-driven tumor cells through a Src-dependent pathway.Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.Protein myristoylation in health and disease.The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancerC-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblastsSrc family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.c-Src drives intestinal regeneration and transformation.Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformationIncreases in c-Src expression level and activity do not promote the growth of human colorectal carcinoma cells in vitro and in vivo.Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-κB and Src protein kinase signaling pathwaysBosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation studyData-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization.Src-mediated phosphorylation of the tyrosine phosphatase PRL-3 is required for PRL-3 promotion of Rho activation, motility and invasionThe SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy.Oncogenic Ras/Src cooperativity in pancreatic neoplasia.Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium.Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.Combination of dasatinib and curcumin eliminates chemo-resistant colon cancer cells
P2860
Q24290329-8AF29F88-7AB9-427D-AB02-6B45C5ACA1F9Q24299210-1E3364FD-1737-44F2-835C-E7C19C318933Q24310538-A332E9FC-1BA7-42DA-B621-A173692570CFQ24616659-DECAA3EA-99AD-4C13-A693-12E43CD31700Q26782593-B12B9F5A-5E79-4202-B6D2-A6ABA8FCF647Q26853018-03F1712F-6973-4C25-9FD1-6BC4DE07E7D1Q27311366-F443AB05-4523-4C4F-AB3B-841FFB0F8BBCQ27851586-8D745089-9B6C-4F7F-9D3C-B3C435B8C7B5Q28391160-A2A69B33-65E3-4510-8B48-0571542CC158Q28535249-995E4A74-433D-41B3-BE14-E8329E302C8CQ28580989-BF5EF079-7400-4E46-B89B-CBD42764C315Q30010169-64A2144E-F1DC-44AD-8183-2305CA3C3C74Q30415151-96269370-B567-4882-9232-83500B2EDE60Q30479068-3283C000-BDBE-46D5-B53E-C4A165113E8AQ30852504-49E1D8BD-207A-4807-A66B-6EF6D4DE6B9EQ30887759-482C83D5-4033-48F9-BBE8-FF1821F0601DQ31133056-F4FAC21C-7981-42E4-8226-B66F9FCB2F0EQ33530940-EFB43CE1-AD5B-4988-9330-BCD378FA3BA8Q33631172-E3F141ED-722D-4DEE-A65A-D841E8281800Q33776733-5F4CEEFE-A827-4001-9EB5-7177AAE3BC81Q33940893-B7318E3D-118B-46F6-8684-9DE446E2A07EQ33966470-E74AD7CB-5025-49CF-AB29-BD4E7563CBEDQ34020051-16380E07-1931-4493-A0B2-3E77E195C2D6Q34067118-2AA8955F-E7A7-4242-A164-E48D35AA06D4Q34119101-C67A7EF3-CE21-4DA2-BC1D-23529E3C3181Q34203648-F890A867-585D-4EE8-9DCA-65BBC0670243Q34324522-1C03F684-A500-4503-892A-3836478C118EQ34480200-225056D6-D0A6-4952-AAC3-C4916B062DC9Q34532048-07DF5C9C-C2E7-452D-8A10-5925558AB2A7Q34541618-79F72045-8EF4-480B-97CD-C74024D078E5Q34585402-E30DFD52-9936-45BF-BDB0-CDD6A047F494Q34603280-0201783F-9EC0-4AD4-810E-CC99DC220E54Q34658293-C3EEB84F-28B6-435A-A59A-2214898F1509Q34671696-410098E3-3E2B-47A8-805D-8F1E7EEEA8D3Q34731436-0FF0B405-A994-40B3-A67E-B4ACA13C33AFQ34966503-D45EF18E-FF35-423F-BB77-7CE873892106Q35015392-1D77A2FF-B23C-43EE-B53F-40A772CA6D08Q35050239-4EC4FF07-D92A-40A7-91EF-9CC916B17629Q35088031-31F74163-5B6D-46A2-AEB1-40D026FCB1C4Q35184278-9181B6DE-A5CE-4478-A7F2-BBD18A18E1A1
P2860
Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer
description
1993 nî lūn-bûn
@nan
1993 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Increase in activity and level ...... ges of human colorectal cancer
@ast
Increase in activity and level ...... ges of human colorectal cancer
@en
Increase in activity and level ...... ges of human colorectal cancer
@nl
type
label
Increase in activity and level ...... ges of human colorectal cancer
@ast
Increase in activity and level ...... ges of human colorectal cancer
@en
Increase in activity and level ...... ges of human colorectal cancer
@nl
prefLabel
Increase in activity and level ...... ges of human colorectal cancer
@ast
Increase in activity and level ...... ges of human colorectal cancer
@en
Increase in activity and level ...... ges of human colorectal cancer
@nl
P2093
P2860
P3181
P356
P1476
Increase in activity and level ...... ges of human colorectal cancer
@en
P2093
G E Gallick
M S Talamonti
S A Curley
P2860
P3181
P356
10.1172/JCI116200
P407
P577
1993-01-01T00:00:00Z